Avacta Group plc (AIM: AVCT), the developer of Affimer® biotheutics and research reagents, announces that application has been made for 3,235 new ordinary shares
Stock analysis for Avacta Group PLC (AVCT:London) including stock price, stock chart, company news, key statistics, fundamentals and company profile.
Avacta has identified 3 Affimer proteins capable of binding to a recombinant form of a secreted Zika virus NS1 protein, which is diagnostic of Zika virus infection
Avacta Group PLC. SEA: UK:AVCT GO. Set Alerts. Find a Broker. • Talk strategies in group discussions • Find or create a game that suits you
Launch of the Sensipod in-clinic blood testing system for vets. First point of care test to provide a canine environmental allergy pre-screen. Avacta Group plc (AIM
Avacta Group plc is the developer of Affimer bio theutics and research reagents. The Company’s segments include Health, which provides tools and contract
Jan 20, 2017 · Updated annual cash flow statement for Avacta Group PLC – including AVCT operating expenses, operating cash flow, net cash flow, cash dividends, other
Jan 19, 2017 · Avacta Group plc – Business update and notice of results. skip to main content Home; About us. At a glance; Our values; Board of Directors; Business model.
Avacta Group Plc. Avacta’s principal focus is on its proprietary Affimer® platform, a novel engineered alternative to antibodies that has wide application in
About Avacta Group plc (www.avacta.com) Avacta’s principal focus is on its proprietary Affimer ® technology which is a novel engineered alternative to antibodies